Drug Profile

ST 01156

Alternative Names: RBM39 degrader therapeutic - SEED Therapeutics; ST-01156

Latest Information Update: 20 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Seed Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action HCC1 autoantigen degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ewing's sarcoma
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

12 Nov 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO), prior to November 2025
12 Nov 2025 China's NMPA clears the IND application for ST 01156 for Solid tumours in China
12 Nov 2025 Seed Therapeutics plans a phase I global expansion trial for Solid tumours and Haematological magnancies in USA, Europe, China, and other countries (PO) in the first quarter of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com